Fibronectin is essential for hepatitis B virus propagation in vitro: May be a potential cellular target?

Biochemical and Biophysical Research Communications

Volumn 344, Issue 3, 2006, Pages 757-764

  Yang, Jing ^a   Ding, Xiaoran ^a   Zhang, Yi ^a   Bo, Xiaochen ^a   Zhang, Minli ^a   Wang, Shengqi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Cellular target; Fibronectin; Hepatitis B virus

Indexed keywords

ADEFOVIR; ANTISENSE OLIGONUCLEOTIDE; FIBRONECTIN; FIBRONECTIN ANTIBODY; LAMIVUDINE; PROTEIN ANTIBODY; PROTOCATECHUALDEHYDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; CELL LINE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FIBRONECTINS; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 33646133430     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.03.204     Document Type: Article

References (20)

1. Seeger C., and Mason W.S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 64 1 (2000) 51-68
2. Park S.G., Lee S.M., and Jung G. Antisense oligodeoxynucleotides targeted against molecular chaperonin Hsp60 block human hepatitis B virus replication. J. Biol. Chem. 278 41 (2003) 39851-39857
3. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 80 (1999) 827-841
4. Feld J., Lee J.Y., and Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 38 3 (2003) 545-553
5. Früh K., Simmen K., and Mattias B.G.L. Virogenomics: a novel approach to antiviral drug discovery. DDT 6 12 (2001) 621-626
6. Kellam P. Attacking pathogens through their host. Genome Biol. 7 (2006) 201
7. Sells M.A., Zelent A.Z., Shvartsman M., and Acs G. Replication hepatitis B virus in HepG2 cells that produce infectious virions. J. Virol. 62 (1988) 2836-2844
8. Sells M.A., Chen M.L., and Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA 84 4 (1987) 1005-1009
9. Yang J., Bo X.C., Yao J., Yang N.M., and Wang S.Q. Differentially expressed cellular genes following HBV: potential targets of anti-HBV drugs?. J. Viral Hepat. 12 (2005) 357-363
10. Yang J., Bo X.C., Ding X.R., Dai J.M., Zhang M.L., Wang X.H., and Wang S.Q. Antisense oligonucleotides targeted against asialoglucoprotein receptor 1 block human hepatitis b virus replication. J. Viral. Hepat. 13 (2006) 158-165
11. Matsui S., Takahashi T., Oyanagi Y., Takahashi S., Boku S., Takahashi K., Furukawa K., Arai F., and Asakura H. Expression, localization and alternative splicing pattern of fibronectin messenger RNA in fibrotic human liver and hepatocellular carcinoma. J. Hepatol. 27 5 (1997) 843-853
12. Julkunen I., Hautanen A., and Keski-Oja J. Interaction of viral envelope glycoproteins with fibronectin. Infect. Immun. 40 (1983) 876-881
13. Keski-Oja J., Hautanen A., and Julkunen J. Fibronectin and viral pathogenesis. Rev. Infect. Dis. 9 (1987) 404-411
14. Greco G., Pal S., Pasqualini R., and Schnapp L.M. Matrix fibronectin increases HIV stability and infectivity. J. Immunol. 168 11 (2002) 5722-5729
15. Liu X., and Collodi P. Novel Form of Fibronectin from Zebrafish Mediates Infectious Hematopoietic Necrosis Virus Infection. J. Virol. 76 2 (2002) 492-498
16. Boshuizen J.A., Rossen J.W., Sitaram C.K., Kimenai F.F., Simons-Oosterhuis Y., Laffeber C., Büller H.A., and Einerhand A.W. Rotavirus enterotoxin NSP4 binds to the extracellular matrix proteins laminin-β3 and fibronectin. J. Virol. 78 18 (2004) 10045-10053
17. Grubman M.J., and Baxt B. Foot-and-mouth disease. Clin. Microbiol. Rev. 17 2 (2004) 465-493
18. Norton P.A., Reis H.M., Prince S., Larkin J., Pan J., Liu J., Gong Q., Zhu M., and Feitelson M.A. Activation of fibronectin gene expression by hepatitis B virus x antigen. J. Viral. Hepat. 11 4 (2004) 332-341
19. Kraemer K., Fuessel S., Schmidt U., Kotzsch M., Schwenzer B., Wirth M.P., and Meye A. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res. 9 10 (2003) 3794-3800
20. Budkowska A., Bedossa P., Groh F., Louise A., and Pillot J. Fibronectin of human liver sinusoids binds hepatitis B virus: identification by an anti-idiotypic antibody bearing the internal image of the pre-S2 domain. J. Virol. 69 2 (1995) 840-848